Radius Health Inc. | Ownership
Companies that own Radius Health Inc.
Bellevue Asset Management AG
6,590,276
14.49%
389,363
1.96%
08/20/2018
T. Rowe Price Associates, Inc.
3,737,540
8.22%
-415,387
0.01%
07/31/2018
The Vanguard Group, Inc.
3,431,669
7.55%
141,866
0%
06/30/2018
BlackRock Fund Advisors
3,019,208
6.64%
181,223
0%
06/30/2018
HealthCor Management LP
2,975,000
6.54%
950,000
1.77%
08/06/2018
Millennium Management LLC
2,939,090
6.46%
2,472,534
0.08%
08/31/2018
SSgA Funds Management, Inc.
2,864,384
6.3%
26,390
0%
06/30/2018
Wellington Management Co. LLP
2,443,366
5.37%
7,891
0.01%
06/30/2018
TimesSquare Capital Management LLC
2,333,586
5.13%
85,100
0.27%
06/30/2018
Farallon Capital Management LLC
2,043,149
4.49%
-2,043,151
0.28%
08/13/2018
| Address |
950 Winter Street
Waltham Massachusetts 02451
United States
|
|
Employees
|
- |
| Website |
http://www.radiuspharm.com |
| Updated |
07/08/2019 |
| Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The firm's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. |
